Randox Biosciences Resource Hub

Home - education

Randox Biosciences Resource Hub

Resource Hub | Biosciences

  • Brochures
  • Clinical Studies Group Publications
  • Flyers
  • Videos

Biosciences overview

Immunology

Proteomics- OLINK Technology

CDx & Biopharma Services

Molecular Testing

Genomics Services

Life Science Product List

Cardiovascular & Metabolic

Acute Kidney Injury

2019.Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score

Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score - 2019

2021.Blood and urinary cytokine balance and renal outcomes at cardiac surgery

Blood and urinary cytokine balance and renal outcomes at cardiac surgery - 2021

2020.Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score

Acute kidney injury risk in orthopaedic trauma patients pre- and post-surgery using a biomarker algorithm and clinical risk score - 2020

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Stratifying Risk of Acute Kidney Injury in Pre- and Post-Cardiac Surgery Patients Using a Novel Biomarker Based Algorithm and Clinical Risk Score - 2020

ARID

2022.Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies

Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies - 2022

Diabetic Nephropathy

_2021_Harkin_On_tissue_chemical_derivatization_in_mass_spectrometry_imaging

On tissue chemical derivatization in mass spectrometry imaging - 2021

2022.Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomar

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomarkers - 2022

2023.Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry Reactive al

Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry: Reactive aldehydes as potential markers of diabetic nephropathy - 2023

HABIO

2019.op68-value-engineered-translation-an-example-for-bladder-cancer-diagnosis

op68 value engineered translation an example for bladder cancer diagnosis - 2019

2020.Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival

Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival - 2020

2022.Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific

Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific - 2022

2024.Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics

Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics - 2024

HABIO Diabetes

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria - 2022

MACE

2022.A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers.pdf

A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers - 2022

MAST4Health

2018. The 9th Santorini Conference- Systems Medicine

The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September – 3 October 2018

2018.The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F

The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F - 2018

2019.Peripheral blood mononuclear cells extracts VEGFprotein levels and VEGF mRNA- Associations with inflammatory molecules in a healthy population

Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population - 2019

2020.Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration

Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration - 2020

2021.A genetic determinant of VEGF-A levels is associated with telomere attrition

A genetic determinant of VEGF-A levels is associated with telomere attrition - 2021

2021.Epigenome-wide association study detects a novel loci associated with central obesity in healthy subjects

Epigenome‑wide association study detects a novel loci associated with central obesity in healthy subjects - 2021

2021.Nutrigenetic Interactions Might Modulate the Antioxidant and AntiInflammatory Status in MastihaSupplemented Patients With NAFLD

Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-inflammatory Status in Mastiha-Supplemented Patients With NAFLD - 2021

2022.Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study

Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study - 2022

2022.Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS)

Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS) - 2022

Myocardial Infarction

2018.diagnostic-performance-of-a-combination-biomarker-algorithm-for-ruleout-of-acute-myocardial-infarction-at-time-of-presentation-to-2155-9880-1000600

Diagnostic Performance of a Combination Biomarker Algorithm for Rule- Out of Acute Myocardial Infarction at Time of Presentation to the Emergency Department, Using Heart-Type Fatty Acid-Binding Protein and High-Sensitivity Troponin T tests - 2018

2019.AnAlgorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction

An Algorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction - 2019

NASH / NAFLD

2022.Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease

Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease - 2022

Polypharmacy

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

A review of the prescribing culture of anti-depressants across government districts in Northern Ireland - 2023

Post-Traumatic Stress Disorder

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

The Intensity and Impact of Chronic Pain, a Story of Difficulty Sleeping and Post-Traumatic Stress Disorder - 2019

2020.Sleep, a Governor of Morbidity in PTSD-A Systematic Review of Biological Markers in PTSDRelated Sleep Disturbances

Sleep, a Governor of Morbidity in PTSD: A Systematic Review of Biological Markers in PTSD-Related Sleep Disturbances - 2020

2021.Post-traumatic stress disorder- A biopsychosocial case-control study investigating peripheral blood protein biomarkers

Post-traumatic stress disorder: A biopsychosocial case-control study investigating peripheral blood protein biomarkers - 2021

2022.ABSTRACT.improving-sleep-in-a-population-at-high-risk-of-trauma-a-pilot-study-examining-self-reported-sleep-psychological-symptomology-and-actigraphy-measured-night-t

Improving sleep in a population at high risk of trauma: A pilot study examining self-reported sleep, psychological symptomology and actigraphy measured night-time sleep - 2022

2022.Post-traumatic stress disorder; identifying potential differences in participant response to CAPS-5 life events checklist questionnaire based on gender

Post-Traumatic Stress Disorder: Identifying Potential Differences in Participant Response to CAPS-5 Life Events Checklist Questionnaire Based on Gender - 2022

2023.Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder

Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder - 2023

2023. REVIEW. Post-Traumatic Stress Disorder- Sleep Disturbances and Biomarkers

Post-Traumatic Stress Disorder: Sleep Disturbances and Biomarkers - Review - 2023

Pre-eclampsia

2024.Feto-maternal indicators of cardiac dysfunction as a justification for the cardiac origins for pre-eclampsia

Feto-maternal indicators of cardiac dysfunction as a justification for the cardiac origins for pre-eclampsia - 2024

Prostate Cancer

2019.ABSTRACT.McNAlly_et_al_diagnostic_classifiers_for_stratifying_patients_at_risk_of_prostate_cancer

Diagnostic classifiers for stratifying patients at risk of prostate cancer - 2019

2020.Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer-A Literature Review

Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review - 2020

2022.A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer

A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer - 2022

Oncology

Randox & Transgene SS

Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus- 2023

Biosciences Bioreagents

Type 1 Diabetes Flyer

Biochip Array Technology

Rapid Stratification of ARDs Flyer

OMICS Services

APOE4 Flyer

Your Next Chosen Partner

Randox Bioreagents- MAbs

Drug Induced Kidney Injury panel

Randox Bioreagents Recombinant Proteins

Biochip Overview

Biosciences Overview Video

Randox Multiplex Stroke Biochip

Randox Bioreagents- Polyclonal Abs

Randox Bioreagents- Overview

STI Campaign Video

Acute Kidney Injury

Randox Coronavirus Biochip Video


Welcome to Vivasuite!

Vivasuite | The Digital Ecosystem for Vivalytic

Connectivity at the Point of care

 

 

Welcome to Vivasuite!

 

Enabling the management of multiple devices remotely, Vivasuite is the digital healthcare ecosystem  allowing users to stay up to date with the latest tests and system updates.

Register your interest

Running within the Bosch IoT cloud maintaining the highest standard of IT security and data privacy. Connectivity ensures that devices are always available and fully updated.

 

 

Advantages of Vivasuite:

 

– Schedule remote software updates

– Know when your devices were last synchronised

– View all devices in one dashboard

– View device information and general device data

View testing history from one system

– Mobile device monitoring

– Vivalytic user management

– Save time with less “on-device” work

Vivalytic Overview

Discover more about the Vivalytic

 

 


Vivalytic Resource Hub

Vivalytic | Resource Hub

Making a Point to Care

 

  • Brochures
  • Flyers
  • Videos
  • Scientific Papers

Vivalytic

VIVALYTIC MG, MH UP/UU Educational Guide

VIVALYTIC MRSA/SA Educational Guide

Vivalytic Gastroenteritis Educational Guide

Vivalytic Bordetella Edu guide Cover

VIVALYTIC Bordetella Detection & Species Identification Educational Guide

Vivalytic Overview

Discover more about the Vivalytic

 

 

SARS-CoV-2 Dual Target, Flu A/B and RSV

SARS-CoV-2 Dual Target

MPXV (Monkeypox)

Urinary Tract Infection (UTI)

Candida auris

Viral Respiratory Infection Array

Sexually Transmitted Infection Array

C. difficile

Bacterial Meningitis

riTA CT/NG

SARS-CoV-2 Pooling Test

MG, MH, UP/UU Rapid Test

Norovirus

Bordetella

Monkeypox (MPXV)

SARS-CoV-2 Rapid Test

MRSA & MSSA Rapid Test

Rota-, Norovirus & C. difficile

Strep A

UTI For-Use Cases

Randox Vivalytic

Vivalytic Installation & Operator User Guide

Vivalytic: Instructional Promo Video

Vivalytic: COVID-19 Testing Process

Coronavirus Testing on the Vivalytic POC Analyser

EVALUATION OF A MULTIPLEX REAL-TIME PCR ASSAY FOR THE DIAGNOSIS OF SEXUALLY-TRANSMITTED INFECTIONS

RAPID AND ACCURATE DETECTION OF MYCOPLASMATACEAE IN CLINICAL SAMPLES

Rapid and Accurate Detection of Whooping Cough in Clinical Samples

Evaluation of the Vivalytic one Analyser for detecting uropathogenic bacteria and antimicrobial resistances in urine samples of urological patients


What We Do: Cutting-Edge Healthcare Diagnostics

About Randox

You may recognise Randox as the principal sponsor of the world’s most famous steeplechase, the Randox Grand National or as the Team GB Official Diagnostic Health partners ahead of the upcoming Olympics, but for forty years Randox have been focusing on the provision of timely and accurate diagnostic testing and promotion of preventative healthcare.

Disruptive Innovation in Diagnostics and Healthcare

Randox’s proprietary Biochip Technology, the result of a £350 million investment, allows many tests to be run simultaneously, which greatly improves he diagnostic power available to clinicians.

Randox’s diagnostic focus is to undertake comprehensive testing and data analysis to identify risk to health, promote preventative healthcare and improve clinical diagnosis. Aiming to achieve better healthcare outcomes whilst reducing the burden on healthcare services.

Whilst the science is complex, the applications are not. Diagnostic testing takes place every day behind the scenes of GP surgeries, laboratories and hospitals.

Around 70% of all medical decisions are based on laboratory results, and so, not surprisingly, we believe that earlier, more accurate and more accessible diagnostics are the key to improving global health and saving lives.

The Future of Healthcare

We are significantly increasing our UK High Street presence, using the unique national coronavirus testing infrastructure and capacity we invested in during the pandemic to deliver a new range of preventative health checks. Expansion plans will see up over 20 new Randox Health clinics operating in the UK and Northern Ireland by the end of the year. The clinics will provide easy access for millions to a range of diagnostic tests for vitamin deficiencies, hormone imbalances, inherited/genetic conditions and key health concerns including heart, liver and kidney conditions.

Key to the unique range of diagnostic testing available at our growing network of clinics is the testing technologies, facilities and comprehensive, nationwide distribution network rapidly developed by Randox Laboratories to play a key role in meeting the sudden national demand for Covid-19 PCR tests. At the height of the pandemic emergency, Randox were the only laboratory in the UK and Northern Ireland to process over 100,000 PCR tests per day, saving thousands of lives.

Now, with millions of people having become accustomed to regular testing through the pandemic, Randox is combining that familiarity with its own unique Covid-19 experience and infrastructure to deliver real, affordable and preventative healthcare through early diagnostic testing on the High Street.


“Randox believes that in harnessing the achievements of during the pandemic we can help the shift away from the traditional model of sickness management to a new era of truly preventative healthcare. This will benefit individuals and society by improving patient outcomes and considerably reducing the burden on our vital and hard-pressed clinical services” (Randox founder and Managing Director – Dr Peter FitzGerald).

Frequently Asked Questions?

  • What is the vision of Randox?

    The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.

    We have also spent more than £220 million developing our patented Randox Biochip.  This state-of-the-art biochip technology has revolutionised the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.

  • When and why was Randox established?

    Our Managing Director Dr FitzGerald established Randox in 1982 in County Antrim, Northern Ireland, to address the need for accurate and readily available diagnostic tests to improve patient diagnosis.  At that time, doctors only conducted a handful of tests per patient, but now, more than 40 years later, Randox has developed and improved hundreds of tests, with hundreds more in development.

  • What products and service do Randox offer?

    Randox has a broad range of products and services that offer a comprehensive insight into patient diagnosis to facilitate more effective disease management and treatment.

    Our clinical product offering includes diagnostic reagents, quality control, and clinical chemistry analysers.

    Our patented Randox Biochip Technology and associated Immunoassay analysers also have applications for forensic toxicology, food diagnostics, and workplace drug testing.

    Our Randox Health clinics offer a range of health checks across general health, sexual health, respiratory health and more. 

  • Who and where are Randox customers?

    Randox’s focus has traditionally been on healthcare providers, so we have placed our products and services in hospitals, clinics, research and molecular laboratories, food testing, forensic toxicology, life sciences and veterinary laboratories.

    With the establishment of our consumer brand, Randox Health, we also offer our innovative tests directly to the consumer in our Randox Health clinics, located across the UK including London, Liverpool, Manchester, Birmingham, Glasgow, Edinburgh, Holywood and Crumlin.

    We have ambitious plans to roll out a number of new clinics across the United Kingdom and internationally, over the coming months and years.

  • What is the size of the company?

    Our company has grown from a small team of two scientists, to over 3300 employees of 44 nationalities, including 650 research scientists and engineers.

     

  • Where are Randox headquartered and what is the geographical reach?

    Our headquarters are in Crumlin, in County Antrim, Northern Ireland – close to Belfast International Airport.  However, we are a global company and currently have offices and distribution outlets in 145 countries, with manufacturing and R&D capabilities in 4 jurisdictions across 3 continents.

    We are currently relocating our headquarters to the Randox Science Park in Antrim; a £161 million project which will accelerate the development of new products into a wide range of clinical needs, including various cancers, stroke, heart disease and neurodegenerative disorders.

    We are very proud of our global penetration – today, approximately 5% of the world’s population receives medical diagnoses using products from Randox.  That equates to about 400 million people. We also supply 15% of the world’s cholesterol tests, so if you’ve ever had your cholesterol checked,  then there’s a high chance it could have been performed using a Randox product!

  • What are the biggest issues within the health sector?

    Our key observation across the globe is that within healthcare the pressure on resources means there is a focus on the “management of sickness,” rather than preventative care. 

    We know that a focus on early diagnosis and preventative care will improve patient outcomes and reduce the burden on healthcare systems.  Making that paradigm shift is a major challenge.  

    That’s why Randox Health was established – to allow the consumer direct access to our innovative technologies so that they can take control of their health and make appropriate lifestyle changes BEFORE disease manifests and symptoms occur.

Want to know more?

Contact us or visit our dedication to quality webpage.

Our History

Company Values

Our Accreditations


Randox QC Resource Hub

  • Brochures
  • Support Tools
  • Educational Items
  • Posters
  • Industry Articles
  • Webinars
  • Videos
  • Blog
  • Testimonials
The importance of third party controls brochure on the Randox Resource hub

Importance of Third Party Controls

Infectious Disease Controls (Serology)

IQC - Liquid 30 Day Controls

RIQAS Point of Care (RIQAS POC)

Qnostics - Molecular Infectious Disease Controls

QCMD - EQA for Molecular Infectious Disease Testing

International Brochures

Download our brochures in other languages

Serum Indices

The Role of Six Sigma in a Modern QC Strategy

The Cost of Poor Quality in the Clinical Laboratory

How to Establish QC Reference Ranges

Basic QC Statistics

ISO 15189 Requirements for Measurement Uncertainty

Commutability

How To Measure Uncertainty

Which QC is The Right QC - Downloads

Which QC is The Right QC

How Often Is Right For QC - Download

How Often Is Right For QC

The Role of EQA in QC

QC Statistics Infographic - Download

QC Statistics Infographic

The Difference Between IQC & EQA - Download

The Difference Between IQC & EQA

Linearity Verification Clinical Chemistry - Download

Linearity Verification Clinical Chemistry

Linearity Verification Cardiac - Download

Linearity Verification Cardiac

Using QC Multi-rules - Download

Using QC Multi-Rules

Preparing QC - Step-by-Step Guide - Download

Preparing QC - Step-by-Step Guide

Monitoring EQA Performance - Download

Monitoring EQA Performance

Guide to Running QC - Download

Guide to Running QC

RIQAS Frequency - Lipase

RIQAS Past Panels Flyer

Measurement Uncertainty in the Clinical Laboratory – Medical Buyer

Measurement Uncertainty in the Clinical Laboratory – Medical Buyer

Using Sigma metrics and Measurement Uncertainty in QC – MLO

Using Sigma metrics and Measurement Uncertainty in QC – MLO

Webinar: Acusera 24.7 - The Future of QC Data Management.

Webinar - Jesienne spotkanie z Wewnątrzlaboratoryjną Kontrolą Jakości

Webinar | RIQAS Report Interpretation & Troubleshooting `{`PART1`}`

Fully syndromic approach to molecular testing

RIQAS Report Interpretation

The Role of EQA in QC Management

Importance of EQA

The Need for Robust Molecular Quality Assurance in the Wake of the Pandemic

Acusera 24•7 Webinar: Utilisation of QC software and metrics to help identify performance issues

Medlab- 24.7 Webinar with Patrick Else

Importance of Third Party Controls in Molecular Diagnostics

Why is the third party QC important for COVID-19 detection in Molecular testing

SARS-CoV-2 Proficiency Testing

Performance & Statistics - How EQA Can Help You Excel

Smartdocs - How To Guide

Acusera Third Party Controls

True Third Party Controls

Acusera Serum Indices Control

Consolidation

QC Serology Video

Acusera 24.7 Live Online

Guide to Running Quality Control

Medical Lab Professionals Week 2016

Acusera 24•7 Interlaboratory Data Management

Acusera 247 Video

Randox Acusera Quality Controls

Customer Testimonial | Adrian Cudmore NHS

Customer Testimonial | DR Caje Moniz NHS

Customer Testimonial | Dr Rosa Sierra Amor

Customer Testimonial | Dr Bianca Thakkar

Customer Testimonial | Dr. Anil Shah

Customer Testimonial | Dr Pragati Desai

Customer Testimonial | Dr Pramod Ingale

Customer Testimonial | Dr Rajeev Mehta

Customer Testimonial | Dr Simple Bhuptani

Customer Testimonial | Dr SM Patel

Customer Testimonial | Dr Trupti Patel

Customer Testimonial | Dr A Vahed Mulla


Randox sponsors Science Summer School Northern Ireland

About Randox       News        Contact Us

Monday 31st January 2022: Randox sponsors Science Summer School Northern Ireland

An official launch for Science Summer School Northern Ireland 2022 has taken place at the Ryobi headquarters in Carrickfergus.

Ryobi are the headline sponsor of the Science Summer School Northern Ireland event, which aims to inspire young people to become the next generation of scientists with an inspirational programme that mixes the best of STEAM (Science, Technology, Engineering, Arts and Maths) through a series of seminars, discussions and hands-on experiments.

On Friday, the Deputy Mayor of Mid and East Antrim, Lord Andrew Mawson OBE, Richard Mallett, and representatives from the other main sponsors, Terumo Blood and Cell Technologies, Randox, Almac, NRC and IPC Mouldings all gathered in Carrickfergus to officially launch the event which will take place later this year.

The Science Summer School initiative was established in 2012 at St. Paul’s Way Trust School in East London by Lord Andrew Mawson OBE and Professor Brian Cox CBE. The project is now expanding nationally with the aim to make ‘the UK the best place to do science and engineering in the world’.

Deputy Mayor, Councillor Matthew Armstrong, said:

 “Council’s Manufacturing Task Force are delighted to be working with a range of local businesses, schools, universities and partner organisations to bring this exciting opportunity to the borough.

“We are thrilled that this event is now going accessible to young people in Mid and East Antrim.

“Our hope is that they will be inspired to embark on a future in science and maybe even become leaders in that field.”

Managing Director of Ryobi, Marco Emig, said: 

 “Ryobi are delighted to be the headline sponsor of this event.

“Science and the desire to learn more about how our world works, and about how we can use that information to improve how we live our lives, has never been more attractive or relevant as a subject area and a potential career path.

“We are very much looking forward to seeing the creative ideas generated from our young people.”

Lord Mawson OBE said: 

 “The Science Summer School initiative here in Northern Ireland will activate the curiosities of the young people who take part and hopefully inspire them to great things.

“This annual celebratory event and the allied programme of STEAM related activity throughout the year provides a vital catalyst to bring together different partners from education and enterprise.  I am delighted to see so many companies have ‘signed up’ to support our first event this year.

 “There is never a better time to be bringing the Science School Northern Ireland hosted by Professor Cox to Ballymena.”

For further information please contact randoxpr@randox.com

Want to know more?

Contact us using the details below.

Related Pages

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


Evidence Series Resource Hub

Evidence Series | Resource Hub

  • Brochures
  • Flyers
  • Videos
  • Blogs
  • Scientific Posters
  • Whitepapers

Evidence

Evidence Investigator

Evidence MultiSTAT

Evidence+

Evidence Evolution

Biochip Technology Explained

Evidence series Overview

Discover more about the Evidence series

 

Cytokines Flyer

DIKI Renal Flyer

A4 Renal Flyer

AKI Covid-19 Flyer

Evidence Investigator - Molecular Diagnostic Testing

Evidence MultiSTAT Demonstration

Evidence Evolution - World's Most Advanced Immunoanalyser

Evidence Investigator - Myco 9 Array, Step By Step

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS DETECTION OF CANCER BIOMARKERS ON THE RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A DUPLEX BIOCHIP ASSAY FOR THE SIMULTANEOUS DETECTION OF ANTI-THYROGLOBULIN AND ANTI-THYROID PEROXIDASE ANTIBODIES ON THE FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF NEW BIOCHIP ARRAYS FOR THE DETERMINATION OF BIOMARKERS RELATED TO ACUTE KIDNEY INJURY APPLIED TO THE EVIDENCE INVESTIGATOR ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE DETECTION OF PARATHYROID HORMONE APPLIED TO THE EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A HIGHLY MULTIPLEXED MOLECULAR ASSAY FOR DETECTION OF INFECTION IN CF AIRWAYS

Repeatability and within-laboratory precision were assessed (n=80): Assay Repeatability Within-laboratory precision CV (%) CV (%) VCAM-1 4.5 6.8 ICAM-1 5.6 8.8 ESEL 12.8 16.6 PSEL 3.5 4.7 LSEL 5.7 8.2 17.096, 097.105RDRT DEVELOPMENT OF A BIOCHIP ARRAY FOR THE DETECTION OF ADHESION MOLECULES ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY UNAFFECTED BY DHEA-S INTERFERENCE FOR THE ACCURATE MEASUREMENT OF SERUM PROGESTERONE

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE RAPID, SIMULTANEOUS DETECTION OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN 17, ON THE NEW RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

CLINICAL EVALUATION OF A RAPID FULLY-AUTOMATED MULTIPLEX BIOCHIP ARRAY FOR STROKE DIAGNOSIS

DEVELOPMENT OF A NEW BIOCHIP ARRAY APPLIED TO THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER FOR THE SIMULTANEOUS MEASUREMENT OF TSH, FREE T4 AND FREE T3

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE MEASUREMENT OF TOTAL 25-HYDROXYVITAMIN D IN SERUM AND THE ACCURATE CLASSIFICATION OF VITAMIN D STATUS

DEVELOPMENT OF A BIOCHIP ASSAY FOR THE DETECTION OF THYROXINE-BINDING GLOBULIN (TBG) ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

GENETIC DIAGNOSIS OF MONOGENIC OR POLYGENIC FAMILIAL HYPERCHOLESTEROLEMIA IN NORTHERN IRELAND: EVALUATION OF THE RANDOX FH ARRAYS IN COMBINATION WITH THE RANDOX 6SNP POLYGENIC HYPERCHOLESTEROLEMIA ARRAY

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS MEASUREMENT OF DISTINCT FATTY ACID-BINDING PROTEINS (FABPs)

DEVELOPMENT OF A NEW ENZYME-LINKED IMMUNOSORBENT ASSAY KIT TO DETECT NGAL IN HUMAN SERUM AND ITS APPLICATION TO CHRONIC KIDNEY DISEASE

SCREENING AND SELECTION OF ANTIBODIES FOR THE DETECTION OF MIP-1 ALPHA AND ITS APPLICATION TO THE STUDY OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A 4-PLEX BIOCHIP ARRAY FOR THE EARLY DETECTION OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A THIRD GENERATION TSH ASSAY ON THE NEW RANDOM ACCESS EVIDENCE EVOLUTION FULLY AUTOMATED BIOCHIP ANALYSER

APPLICATION OF THE NEW RANDOM ACCESS, FULLY AUTOMATED BIOCHIP ANALYSER EVIDENCE EVOLUTION TO SIMULTANEOUSLY MEASURE ANALYTES RELATED TO ENDOCRINE FUNCTION

STRATIFYING RISK OF ACUTE KIDNEY INJURY IN PRE AND POST CARDIAC SURGERY PATIENTS USING A NOVEL BIOMARKER-BASED ALGORITHM AND CLINICAL RISK SCORE

SARS-CoV-2 Vascular & Multi-System Dysfunction

Acute Kidney Injury and Antimicrobial Stewardship

Alzheimer's Disease, ApoE4 & Risk Detection


The use of DNA, Drug and Alcohol Testing in Medico-Legal cases

18 September 2020: The use of DNA, Drug & Alcohol Testing in Medico-Legal cases

Drug and alcohol testing may be required by various professional bodies involved in child custody cases, care proceedings or child protection cases. In cases regarding divorce and children, a dispute may arise during the process of discussions involving the custody of children. In these cases, drug and alcohol testing may be sought if there has been a substance abuse claim against a parent fighting for custody or visitation. In cases relating to child protection, social services may seek drug and alcohol testing if child welfare claims have been made regarding suspected substance misuse.

Why is Drug and Alcohol Testing in Medico-legal Cases Important?

Drug and alcohol testing is important to ensure child protection from the detrimental effects of parental substance misuse and to ensure they have the quality of life they deserve. In addition, it is also important to allow parents the opportunity to get the help and support they need and begin rehabilitation treatment.

Doing the right thing by the child is the main priority, and where possible parent and child relationships are sought to be maintained. Drug and alcohol testing assists in these efforts and in such cases abstinence monitoring testing may be required to assess a parent’s recovery e.g. if a visitation case is being reassessed.

Our Expertise

At Randox Testing Services we provide drug and alcohol testing to all professionals within the medico-legal sector. Our testing service utilises accredited testing methods and is made more cost-effective through patented testing methods developed by Randox.

We understand the impact a positive result can have on a parent, child, and extended family and ensure results are of the highest precision and accuracy. With over 35 years’ experience in the diagnostic industry we have gained reputation as a trusted provider.

Our drug and alcohol testing solutions are flexible and can be tailored to our customer needs with a choice of testing methods. We offer a comprehensive drugs of abuse test menu and our service also includes the use of an Expert Witness Statement where applicable.

Range of Testing

We provide a range of testing to suit the requirements for any medico-legal case. Read more below to find out what is available.

Alcohol Testing

PEth

PEth (Phosphatidylethanol) is a direct alcohol biomarker that only forms in the body when ethanol is present, making it the most sensitive and specific test to assess alcohol consumption levels.

  • PEth test involves spotting a drop of blood from a small finger prick onto a test card. The dried blood spot (DBS) is sent to the laboratory for analysis.
  • PEth testing will differentiate between abstinence or light alcohol consumption, social alcohol consumption and alcohol abuse for up to a month prior to the test.

Benefits of PEth Testing

  • Accurate blood alcohol test
  • Detect chronic and single-drinking episodes of alcohol consumption
  • Monitor abstinence, drinking behaviour and identify relapse

Hair Alcohol Testing

Testing for alcohol in head hair works by detecting two metabolites of alcohol: ethyl glucuronide (EtG) and the fatty acid ethyl ester (FAEE). Both EtG and FAEE can be measured in hair providing an insight into alcohol consumption over the previous period of months. Concentrations can be influenced by cosmetic treatments and products and as such it is always advisable to test in conjunction with PEth or LFT/CDT blood testing.

Benefits of Hair Alcohol Testing

  • Assessment of alcohol consumption for up to 6 months
  • Collected by fully trained Collection Officer
  • History of alcohol consumption can be established

Blood Alcohol Testing

Blood alcohol testing is used to measure the level of alcohol in an individual’s blood. When alcohol is consumed, it’s absorbed into the bloodstream, with approximately 90% being broken down into the liver. RTS offer the following blood alcohol tests:

  • Liver Function Test (LFT) – The blood is examined for specific enzymes which can indicate damage to the liver caused by alcohol consumption. However, other factors can lead to increased levels of liver enzymes.
  • Carbohydrate Deficient Transferrin (CDT) – Looks at specific protein which can become elevated because of heavy alcohol consumption. However, other factors can lead to increased levels of CDT.

Benefits of Blood Alcohol Testing

  • Collection by a fully trained phlebotomist collection officer
  • Assessment of alcohol consumption for up to 1 month
  • Determine drinking behaviour and patterns of use

Drug Testing

Urine

Urine drug testing is used to determine whether someone is misusing drugs by taking a sample of their urine. We offer a 12 panel that covers the major drug groups, including:

Opiates, MDMA/Ecstasy, Cocaine, Tramadol, Methadone, Methamphetamine, Ketamine, Amphetamine, Cannabinoids, EDDP, Benzodiazepines, Buprenorphine

Benefits of Urine Drug Testing

  • Assessment of substance consumption for up to 12 days, drug dependent and quantity ingested
  • Confirmation of presumptive positive available on request
  • Fully accredited LC mass spectrometry confirmatory analysis

Hair

Hair drug testing is a useful form of testing and can be used to support other methods such as oral fluid and urine testing. Our standard panel for hair drug testing includes:

Opiates, Methadone, Tramadol, Cocaine (inc. Crack Cocaine), Amphetamines, (inc. Methamphetamines and “ecstasy” type drugs), Benzodiazepines, Cannabis, Ketamine

Benefits of Hair Drug Testing

  • Detection window of 0-12 months dependent on length (1cm roughly 1 month) – Can be an overview of 3 monthly periods or segmented into monthly periods.
  • Head hair & body hair (except axillary & pubic)
  • Body hair – Up to a 12-month overview. Unable to be segmented
  • Bespoke hair drug panel with other substances available on request

DNA Testing

We provide a range of DNA Testing services to suit your requirements.

  • Paternity testing
  • Maternity testing
  • Sibling DNA testing
  • Grandparent DNA testing
  • Aunt/Uncle testing

Benefits of DNA Testing

  • Fully trained collection officer
  • Legally accepted results

Want to find out more?

To speak to one of our experts about how our range of testing and services can help with your medico-legal testing enquiry, contact us today by emailing testingservices@randox.com or by phoning +44 (0) 28 9445 1011

 

Want to know more?

Contact us or visit our website to read more.


Drug and Alcohol Training from Randox Testing Services

10 August 2020: Drug and Alcohol Training from Randox Testing Services

As well as providing a fully managed drug & alcohol testing service, RTS provide a range of training and education services to help inform and educate regarding the issue of drug & alcohol use in the workplace.

Alcohol use increases the risk of problems in the workplace, such as absenteeism, presenteeism and inappropriate behaviour. Use of alcohol or illicit drugs can impair a person’s performance at work through poor decision making and impaired reaction times causing lost productivity, inferior goods/services, errors and accidents.

Certain working situations and conditions are associated with use of alcohol and illicit drugs (i.e. shift or night work, travel away from home, working remotely, business meals, poor communications and job stress, etc). There are many factors within the workplace culture that present an increased risk for the use of substances including availability, work/peer-group pressures, lack of supervision, physical danger and interface with a demanding or aggressive public. International evidence also indicates that longer working hours are significantly associated with higher rates of alcohol use and related problems.

Professional Services

Randox Testing Services offer professional training services to ensure efficient implementation of workplace drug and alcohol testing. The training services confirm employer confidence to carry out workplace drug and alcohol testing and management competence in enforcing the process. There are a range of tailored training programmes to educate employers and their management staff.

Range of Courses

Our range of competency courses are designed to train employees who will be responsible for carrying out self-collection in accordance with company policy. Anyone involved in self-collection needs to be suitably trained and certificated to follow set procedures that ensure all testing can be legally defended. We provide competency courses for the following matrices:

  • Alcohol Testing
  • Instant Urine Testing
  • Instant Oral Fluid Testing

In addition to the above, we also provide a portfolio of other training and education presentations that enable employers to enhance awareness of substance misuse & understand the various processes involved when implementing a workplace testing programme. These options include:

  • Chain of Custody Training
  • Drug & Alcohol Awareness Training
  • Employee Briefings
  • Bespoke Training Courses

All training courses are fully recorded, regularly reviewed and include an assessment of the effectiveness of training. Upon completion, all attendees are granted a Certificate of Attendance at the end of each completed training course.

Randox Testing Services

Randox Testing Services are a specialist in the workplace drug & alcohol testing sector. We provide a wide range of testing for companies who want to reduce the impact of substance misuse in the workplace. With a range of service options and expert staff on hand to provide help and training, our services will help to eradicate the impact of drugs and alcohol.

If you have any questions regarding drug & alcohol testing and how we can provide your company with training and education services, please use the below details to get in touch and we will be happy to discuss requirements.

Email – testingservices@randox.com

Phone – +44 (0) 28 9445 1011

Want to know more?

Contact us or visit our website to read more.


FAQs for Media

Frequently Asked Media Questions

Randox have almost 40 years of experience as a primary manufacturer in the IVD (in vitro diagnostics) industry. Last year we manufactured over 3 billion tests and exported to 145 countries. Randox are an ISO 13485 accredited manufacturer of in-vitro diagnostic medical devices, are a provider of a global laboratory accreditation scheme (RIQAS) accredited to ISO 17043, and run a number of ISO 17025 accredited laboratories. As an exporter to 145 countries and a manufacturer to other diagnostic companies we undergo multiple external audits each year, in order to remain engaged with our global markets.

At the time of the emergence of the COVID-19 threat, Randox had already developed seven CE marked assays for a range of viruses, including a number of other coronaviruses.

Upon identifying the latest strain of coronavirus as a significant global threat, Randox was able to harness our R&D capability, and some 40 years’ in diagnostics, including viral tests, to develop an effective COVID-19 assay with the same rigorous validation processes that we applied to all our other assays.

The Randox COVID-19 test underwent evaluation within, and was accepted by, Public Health England.

In its evaluation of the Randox COVID-19 test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.

 

As one of the UK’s major life sciences companies, providing diagnostic capabilities both within the UK and globally for almost 40 years, Randox has maintained regular contact with senior officials directly responsible for Life Sciences in the UK, particularly in the fields of diagnostic capability and innovation. We had developed our COVID-19 testing capability by mid-February 2020, and notified officials as such.

Over a number of weeks, we worked collaboratively with government to determine how best we might be able to support the national testing programme.

Our contribution to this programme, which was announced on 27th March, was the culmination of significant engagement, from the identification of the threat, until that date.

The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test. When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.

Randox are providing high volume testing within our laboratories.

It should be noted that Randox is only one partner within a multi-partner, national testing programme being run and coordinated by the Department of Health and Social Care.

In order for the testing programme to work efficiently, all partners work to ensure effective processes at each stage of the testing journey – from testing kit distribution and sample collection to transportation and delivery, and finally, the testing of the sample.

For our part, we are focused diligently on processing all tests in a timely manner after receipt of sample at our laboratory.

It is our priority to ensure that we support the national effort to fight COVID-19, by testing at scale, as we know that this is the most effective way to save lives and promote a timely return to a more normal society.

PHE managed the validation process for each of England, Wales, Scotland and Northern Ireland.

We understand that the national plan for COVID-19 testing is exactly that, a national plan, inclusive of Northern Ireland. The planning for the national distribution of test kits is being managed by the various statutory agencies however Randox made the case that tests should be made available locally.

Following that engagement, Randox tests were made directly available within Northern Ireland, and sent, for example, to the drive-through test centre at the SSE arena.

Randox will continue to support Northern Ireland within the UK national plan.

The Randox COVID-19 test is a molecular-based test which looks for SARS-CoV-2 (the virus that causes COVID-19) within the body.  PCR (Polyamerase Chain Reaction) techniques are used to detect viral RNA (ribonucleic acid) contained inside the SARS-CoV-2 virus.

The Randox COVID-19 assay conducts two tests – one specific and one confirmatory – as recommended by the World Health Organisation and the Centres for Disease Control and Prevention.

The majority of results are reported within 24 hours of receipt of sample at our laboratories.

The Health Secretary, Matthew Hancock, acknowledged that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which helps explain the variation between the UK and other countries.

Read an Opinion Piece from our Managing Director, Dr Peter FitzGerald, on the Telegraph Online, by clicking here.

In support of our role within the national testing programme we have invested £85m since March 2020 in the building and equipping of over 80,000 sq ft of molecular laboratory space and the development of new innovations in testing technology in our COVID-19 testing facilities at the Randox Science Park in Northern Ireland.

We have hired more than 850 new staff, and are recruiting for an additional 400 across science, accessioning, customer support and manufacturing.

Find out more here.

 

On 9th April 2021, Randox processed its 12 millionth sample within the UK COVID-19 National Testing Programme, representing approximately 21% of all PCR tests executed in the UK.

As we continue to ramp up our testing capabilities, and work alongside the government to offer this testing to an increasing list of individuals, we also recognize a demand for testing from the general public – for COVID-safe travel and business.

The Randox COVID-19 test is available to purchase as part of our ‘Get Back to Business’ COVID-19 testing service, for staff screening.

On 13th April 2021 Randox announced its support for British holidaymakers and the travel industry by reducing the cost of its PCR travel test to £60. In order to achieve the £60 price, purchasers will need to apply a discount code which can be obtained from airlines when booking travel. Major airlines including British Airways, Jet2, Easyjet and Ryanair have signed up to provide discount codes for their passengers.⠀

Yes, Randox can conduct antibody testing.

Find out more here.

For COVID-19 press enquiries please email randox@newcenturymedia.co.uk

Want to know more?

Contact us or visit our news page.

Newspage

What We Do

Contact Us


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro Ćŗltimo seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×